Skip to main content

Soleno Therapeutics Inc

SLNODelisted
Industry
Pharmaceutical Preparations
SEC CIK
0001484565

Soleno Therapeutics Inc was delisted in 2026; its insiders filed their last Form 4 on May 18, 2026; 227 institutions reported holding it in 13F filings for Q1 2026, worth $2.09B in total; no superinvestor held it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Soleno Therapeutics Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Soleno Therapeutics Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Soleno Therapeutics Inc
NameTitleLast reported holdingLast filingFilings, past year
Hahn Mark WDirector0May 18, 20262
Pauls MatthewDirector0May 18, 20261
Anish BhatnagarCHIEF EXECUTIVE OFFICER0May 18, 20263
Yen KristenSEE REMARKS0May 18, 20263
Bir Dawn CarterDirector0May 18, 20261
Manning MeredithChief Commercial Officer0May 18, 20264
Volck BirgitteDirector0May 18, 20261
Sinclair AndrewDirector0May 18, 20261
Hirano Patricia CSEE REMARKS0May 18, 20263
Norrett KevinChief Business Officer0May 18, 20263
Fulk JenniferCHIEF FINANCIAL OFFICER0May 18, 20262
Joshi ManherChief Development Officer0May 18, 20263
Huang Michael F.Sr. VP of Clinical Development0May 18, 20264
Mackaness James HCHIEF FINANCIAL OFFICER131,763Jan 23, 20262
Harris William GDirector19,392Jun 9, 20250
Vivo Opportunity, LLC10% Owner4,458,294IndirectMar 28, 20250
Vivo Opportunity Fund Holdings, L.P.10% Owner4,458,294IndirectMar 28, 20250
Urbanski Raymond W.CHIEF DEVELOPMENT OFFICER–Aug 23, 20240
Mario ErnestDirector193,066Jun 10, 20240
TC Group, LLC10% Owner1,531,436IndirectOct 2, 20230
Carlyle Investment Management LLC10% Owner1,531,436IndirectOct 2, 20230
Abingworth LLP10% Owner1,531,436IndirectOct 2, 20230
Carlyle Group Inc.10% Owner1,531,436IndirectOct 2, 20230
Carlyle Holdings I GP Inc.10% Owner1,531,436IndirectOct 2, 20230
Carlyle Holdings I GP Sub L.L.C.10% Owner1,531,436IndirectOct 2, 20230
Carlyle Holdings I L.P.10% Owner1,531,436IndirectOct 2, 20230
Abingworth Bioventures VII LP10% Owner1,531,436IndirectOct 2, 20230
CG Subsidiary Holdings L.L.C.10% Owner1,531,436IndirectOct 2, 20230
Carlyle Genesis UK LLC10% Owner1,531,436IndirectOct 2, 20230
Edelman Joseph10% Owner3,074,542IndirectSep 28, 20230
Perceptive Advisors LLC10% Owner3,074,542IndirectSep 28, 20230
Perceptive Life Sciences Master Fund Ltd10% Owner3,074,542IndirectSep 28, 20230
Melincoff Gwen ADirector–May 26, 20230
Schuler Jack W10% Owner36,595IndirectMay 15, 20230

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Mar 31, 2026 (view filing)Mar 274 daysHuang Michael F.Sr. VP of Clinical DevelopmentSSale−6.58K$30.44−$200.4K−14.2%39.8K after3 lots
Mar 31, 2026 (view filing)Mar 274 daysManning MeredithChief Commercial OfficerSSale−7.52K$30.44−$229.0K−10.4%64.5K after3 lots
Jul 3, 2025 (view filing)Jul 12 daysHirano Patricia CSEE REMARKSSSale−3.83K$82.76−$317.0K−22.5%13.2K after10b5-1
Jun 26, 2025 (view filing)Jun 242 daysHirano Patricia CSEE REMARKSSSale−266$84.25−$22.4K−1.5%17.0K after10b5-1
Apr 2, 2025 (view filing)Apr 11 dayHirano Patricia CSEE REMARKSSSale−3.78K$70.11−$265.2K−12.3%27.0K after10b5-1
Mar 31, 2025 (view filing)Mar 283 daysPauls MatthewDirectorSSale−5.94K$71.55−$424.8K−47.7%6.50K after
Mar 31, 2025 (view filing)Mar 274 daysYen KristenSEE REMARKSSSale−95.5K$66.77−$6.38M−77.2%28.1K after10 lots
Mar 31, 2025 (view filing)Mar 274 daysManning MeredithChief Commercial OfficerSSale−45.2K$67.28−$3.04M−49.9%45.4K after9 lots
Mar 31, 2025 (view filing)Mar 274 daysMackaness James HCHIEF FINANCIAL OFFICERSSale−90.6K$69.45−$6.29M−46.3%105.2K after11 lots
Mar 31, 2025 (view filing)Mar 274 daysHuang Michael F.Sr. VP of Clinical DevelopmentSSale−14.6K$69.51−$1.01M−28.4%36.8K after9 lots
Mar 31, 2025 (view filing)Mar 27-284 daysHirano Patricia CSEE REMARKSSSale−156.3K$68.51−$10.7M−83.5%30.8K after16 lots10b5-1
Mar 31, 2025 (view filing)Mar 274 daysAnish BhatnagarCHIEF EXECUTIVE OFFICERSSale−699.1K$67.62−$47.3M−54.8%577.1K after12 lots
Mar 28, 2025 (view filing)7:03 PM ETMar 26-282 daysVivo Opportunity, LLC and 1 other10% OwnerSSale−1.83M$67.87−$124.4M−29.1%4.46M after3 lots
Jan 6, 2025 (view filing)Jan 2-34 daysYen KristenSEE REMARKSSSale−4.86K$45.78−$222.5K−6.0%76.6K after3 lots
Jan 6, 2025 (view filing)Jan 2-34 daysMackaness James HCHIEF FINANCIAL OFFICERSSale−7.87K$45.78−$360.5K−6.6%111.3K after3 lots
Jan 6, 2025 (view filing)Jan 2-34 daysHirano Patricia CSEE REMARKSSSale−3.03K$45.78−$138.7K−2.8%105.9K after3 lots
Jan 6, 2025 (view filing)Jan 2-34 daysAnish BhatnagarCHIEF EXECUTIVE OFFICERSSale−21.1K$45.78−$965.6K−2.9%698.5K after3 lots
Oct 3, 2024 (view filing)Oct 12 daysYen KristenSEE REMARKSSSale−3.11K$49.43−$153.6K−3.7%81.5K after2 lots
Oct 3, 2024 (view filing)Oct 12 daysMackaness James HCHIEF FINANCIAL OFFICERSSale−8.08K$49.43−$399.3K−6.3%119.2K after2 lots
Oct 3, 2024 (view filing)Oct 12 daysHirano Patricia CSEE REMARKSSSale−3.11K$49.43−$153.6K−2.8%108.9K after2 lots
Oct 3, 2024 (view filing)Oct 12 daysAnish BhatnagarCHIEF EXECUTIVE OFFICERSSale−21.6K$49.43−$1.07M−2.9%719.6K after2 lots
Aug 30, 2024 (view filing)Aug 28-292 daysYen KristenSEE REMARKSSSale−10.7K$47.43−$507.7K−11.2%84.6K after4 lots
Aug 30, 2024 (view filing)Aug 28-292 daysMackaness James HCHIEF FINANCIAL OFFICERSSale−13.5K$47.43−$641.8K−9.6%127.2K after4 lots
Aug 30, 2024 (view filing)Aug 28-292 daysHirano Patricia CSEE REMARKSSSale−10.7K$47.43−$507.7K−8.7%112.0K after4 lots
Aug 30, 2024 (view filing)Aug 28-292 daysAnish BhatnagarCHIEF EXECUTIVE OFFICERSSale−115.0K$47.43−$5.45M−13.4%741.2K after4 lots
Aug 29, 2024 (view filing)7:36 PM ETAug 27-292 daysVivo Opportunity, LLC and 1 other10% OwnerSSale−1.02M$48.01−$49.2M−14.0%6.29M after3 lots
Aug 7, 2024 (view filing)Aug 5-62 daysYen KristenSEE REMARKSSSale−11.0K$45.60−$500.4K−10.3%95.3K after5 lots
Aug 7, 2024 (view filing)Aug 5-62 daysMackaness James HCHIEF FINANCIAL OFFICERSSale−15.0K$45.60−$683.2K−9.6%140.8K after5 lots
Aug 7, 2024 (view filing)Aug 5-62 daysHirano Patricia CSEE REMARKSSSale−11.0K$45.60−$502.0K−8.2%122.7K after5 lots
Aug 7, 2024 (view filing)Aug 5-62 daysAnish BhatnagarCHIEF EXECUTIVE OFFICERSSale−127.3K$45.60−$5.81M−12.9%856.2K after5 lots
Jul 3, 2024 (view filing)Jul 12 daysYen KristenSEE REMARKSSSale−2.17K$41.54−$90.1K−9.3%21.3K after2 lots
Jul 3, 2024 (view filing)Jul 12 daysMackaness James HCHIEF FINANCIAL OFFICERSSale−7.19K$41.54−$298.7K−11.4%55.8K after2 lots
Jul 3, 2024 (view filing)Jul 12 daysHirano Patricia CSEE REMARKSSSale−2.17K$41.54−$90.1K−4.3%48.8K after2 lots
Jul 3, 2024 (view filing)Jul 12 daysAnish BhatnagarCHIEF EXECUTIVE OFFICERSSale−19.3K$41.54−$799.9K−12.6%133.5K after2 lots
May 1, 2024 (view filing)1:10 PM ETApr 29-302 daysVivo Opportunity, LLC and 1 other10% OwnerSSale−1.10M$46.95−$51.7M−13.1%7.32M after2 lots
Apr 3, 2024 (view filing)Apr 12 daysYen KristenSEE REMARKSSSale−2.22K$41.34−$91.7K−8.7%23.4K after2 lots
Apr 3, 2024 (view filing)Apr 12 daysMackaness James HCHIEF FINANCIAL OFFICERSSale−5.17K$41.34−$213.9K−7.6%63.0K after2 lots
Apr 3, 2024 (view filing)Apr 12 daysHirano Patricia CSEE REMARKSSSale−2.22K$41.34−$91.7K−4.2%50.9K after2 lots
Apr 3, 2024 (view filing)Apr 12 daysAnish BhatnagarCHIEF EXECUTIVE OFFICERSSale−19.0K$41.34−$784.6K−11.0%152.8K after2 lots
Jan 29, 2024 (view filing)Jan 254 daysYen KristenSEE REMARKSSSale−397$48.30−$19.2K−1.5%25.6K after
Jan 29, 2024 (view filing)Jan 254 daysHirano Patricia CSEE REMARKSSSale−832$48.30−$40.2K−1.9%43.1K after
Jan 29, 2024 (view filing)Jan 254 daysAnish BhatnagarCHIEF EXECUTIVE OFFICERSSale−2.53K$48.30−$122.1K−1.4%171.8K after
Dec 15, 2023 (view filing)Dec 13-142 daysHirano Patricia CSee RemarksSSale−6.24K$38.29−$239.1K−23.8%20.0K after2 lots
Dec 14, 2023 (view filing)Dec 12-132 daysYen KristenSee RemarksSSale−37.8K$37.33−$1.41M−94.9%2.04K after3 lots
Dec 13, 2023 (view filing)Dec 112 daysAnish BhatnagarChief Executive OfficerSSale−93.4K$35.67−$3.33M−79.4%24.3K after3 lots
Dec 13, 2023 (view filing)Dec 112 daysMackaness James HChief Financial OfficerSSale−32.5K$36.41−$1.18M−72.8%12.1K after3 lots
Dec 4, 2023 (view filing)Nov 304 daysYen KristenSee RemarksSSale−3.96K$28.65−$113.5K−15.3%21.9K after
Dec 4, 2023 (view filing)Nov 304 daysMackaness James HChief Financial OfficerSSale−4.19K$28.65−$119.9K−16.4%21.3K after
Dec 4, 2023 (view filing)Nov 304 daysHirano Patricia CSee RemarksSSale−3.82K$28.65−$109.5K−12.7%26.2K after
Dec 4, 2023 (view filing)Nov 304 daysAnish BhatnagarChief Executive OfficerSSale−27.7K$28.65−$794.1K−20.4%108.1K after